| ［1］ |
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3): 492-542.
|
| ［2］ |
范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
|
| ［3］ |
Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861.
|
| ［4］ |
Targher G, Byrne CD, Tilg H. MASLD: A systemic metabolic disorder with cardiovascular and malignant complications[J]. Gut, 2024, 73(4): 691-702.
|
| ［5］ |
Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864.
|
| ［6］ |
Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023, 165(4): 1025-1040.
|
| ［7］ |
Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6): 497-509.
|
| ［8］ |
Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160(3): 912-918.
|
| ［9］ |
Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis[J]. Gastroenterology, 2020, 159(4): 1290-1301, e5.
|
| ［10］ |
Perdomo CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults[J]. Lancet, 2023, 401(10382): 1116-1130.
|
| ［11］ |
Latteri S, Sofia M, Puleo S, et al. Mechanisms linking bariatric surgery to adipose tissue, glucose metabolism, fatty liver disease and gut microbiota[J]. Langenbecks Arch Surg, 2023, 408(1): 101.
|
| ［12］ |
Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis[J]. Surg Obes Relat Dis, 2019, 15(3): 502-511.
|
| ［13］ |
Seeberg KA, Borgeraas H, Hofso D, et al. Gastric bypass versus sleeve gastrectomy in type 2 diabetes: effects on hepatic steatosis and fibrosis: A randomized controlled trial[J]. Ann Intern Med, 2022, 175(1): 74-83.
|
| ［14］ |
Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): A multicentre, open-label, randomised trial[J]. Lancet, 2023, 401(10390): 1786-1797.
|
| ［15］ |
Kraljevic M, Susstrunk J, Wolnerhanssen BK, et al. Long-term outcomes of laparoscopic Roux-en-Y gastric bypass vs laparoscopic sleeve gastrectomy for obesity: the SM-BOSS randomized clinical trial[J]. JAMA Surg, 2025, 160(4): 369-377.
|
| ［16］ |
Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis[J]. JAMA, 2021, 326(20): 2031-2042.
|
| ［17］ |
Elsaid MI, Li Y, Bridges JFP, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease[J]. JAMA Netw Open, 2022, 5(10): e2235003.
|
| ［18］ |
Sandoval DA, Patti ME. Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia[J]. Nat Rev Endocrinol, 2023, 19(3): 164-176.
|
| ［19］ |
Crommen S, Rheinwalt KP, Plamper A, et al. Prognostic characteristics of metabolic dysfunction-associated steatotic liver in patients with obesity who undergo one anastomosis gastric bypass surgery: A secondary analysis of randomized controlled trial data[J]. Nutrients, 2024, 16(18): 3210.
|
| ［20］ |
Wirth KM, Sheka AC, Kizy S, et al. Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: A retrospective cohort analysis[J]. Ann Surg, 2020, 272(1): 32-39.
|
| ［21］ |
Rustgi VK, Li Y, Gupta K, et al. Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity[J]. Gastroenterology, 2021, 161(1): 171-184, e10.
|
| ［22］ |
Dong TS, Katzka W, Yang JC, et al. Microbial changes from bariatric surgery alters glucose-dependent insulinotropic polypeptide and prevents fatty liver disease[J]. Gut Microbes, 2023, 15(1): 2167170.
|
| ［23］ |
Adami GF, Carbone F, Montecucco F, et al. Adipose tissue composition in obesity and after bariatric surgery[J]. Obes Surg, 2019, 29(9): 3030-3038.
|
| ［24］ |
Dang JT, Sheppard C, Kim D, et al. Predictive factors for diabetes remission after bariatric surgery[J]. Can J Surg, 2019, 62(5): 315-319.
|
| ［25］ |
Yoshino M, Kayser BD, Yoshino J, et al. Effects of diet versus gastric bypass on metabolic function in diabetes[J]. N Engl J Med, 2020, 383(8): 721-732.
|
| ［26］ |
Petrov MS, Taylor R. Intra-pancreatic fat deposition: bringing hidden fat to the fore[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(3): 153-168.
|
| ［27］ |
Zhao X, Kwan JYY, Yip K, et al. Targeting metabolic dysregulation for fibrosis therapy[J]. Nat Rev Drug Discov, 2020, 19(1): 57-75.
|
| ［28］ |
Svane MS, Bojsen-Moller KN, Martinussen C, et al. Postprandial nutrient handling and gastrointestinal hormone secretion after Roux-en-Y gastric bypass vs sleeve gastrectomy[J]. Gastroenterology, 2019, 156(6): 1627-1641, e1.
|
| ［29］ |
Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications[J]. Int J Mol Sci, 2020, 21(15): 5214.
|
| ［30］ |
Martinou E, Stefanova I, Iosif E, et al. Neurohormonal changes in the gut-brain axis and underlying neuroendocrine mechanisms following bariatric surgery[J]. Int J Mol Sci, 2022, 23(6): 3339.
|
| ［31］ |
Yang C, Zhu D, Liu C, et al. Lipid metabolic reprogramming mediated by circulating Nrg4 alleviates metabolic dysfunction-associated steatotic liver disease during the early recovery phase after sleeve gastrectomy[J]. BMC Med, 2024, 22(1): 164.
|
| ［32］ |
Myronovych A, Bhattacharjee J, Salazar-Gonzalez RM, et al. Assessment of the role of FGF15 in mediating the metabolic outcomes of murine Vertical Sleeve Gastrectomy (VSG)[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(6): G669-G684.
|
| ［33］ |
Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control[J]. Endocrinology, 2012, 153(8): 3613-3619.
|